Figure S3. Relative Vaccine Efficacies of Goldblatt et al. PCV13 in a Simulated Trial. Relative vaccine efficacies during a vaccine trial simulated under assumptions of less divergence between the efficacies of different dose schedules. (a) Relative VE determined using prevalences. (b) Relative VE determined using prevalence odds. In both sub-figures, the “calculated” relative VE was determined from the initial VE parameters of the simulation according to the formula: Relative VE = 1 – (1 – VEintervention)/(1 – VEreference). (JPG 332 kb
Additional file 1: Supplementary Figure 1. Directed acyclic graph (DAG) on hypothesis 2: Higher reac...
Time taken to reach the peak prevalence varies according to the household size distribution in the c...
The degree and time frame of indirect effects of vaccination (serotype replacement and herd immunity...
Figure S2. Simulated Trial of Goldblatt et al. PCV13 in a 3 + 1 Vaccinated Population. Vaccine trial...
Figure S4. Power vs. Trial Arm Size in a Simulated Trial of Goldblatt et al. PCV13. Simulated under ...
Figure S5. Serotype-specific Prevalence Distribution After Fitting Model. Prevalence of each serotyp...
Additional file 1: Supplemental Figure S1. Vaccine roll-out scenarios. Supplemental Figure S2. Impac...
Adjusted analysis of the association of different variables with the vaccine era using linear mixed ...
Additional file 1: S1 Fig. Effects of full vaccination on the (A) case growth rate, (B) number of IC...
Figure S2. The hazard ratio (HR) for AOM-associated antimicrobial prescriptions from the cox-regress...
Abstract Background There is great interest in the use of reduced dosing schedules for pneumococcal ...
Additional file 1: Table S1. Characteristics of participants with breakthrough infections, post-vacc...
Kinetics of prevalence and evolution of OPV2-derived viruses for the exponential decay pattern in th...
Additional file 1: S1. Model Structure. S1.1. Modelling transmission. S1.2. Fitting to the basic rep...
Additional charts (Figure S1. Vaccination strategy by treatment number. Figure S2. Sensitivity of pr...
Additional file 1: Supplementary Figure 1. Directed acyclic graph (DAG) on hypothesis 2: Higher reac...
Time taken to reach the peak prevalence varies according to the household size distribution in the c...
The degree and time frame of indirect effects of vaccination (serotype replacement and herd immunity...
Figure S2. Simulated Trial of Goldblatt et al. PCV13 in a 3 + 1 Vaccinated Population. Vaccine trial...
Figure S4. Power vs. Trial Arm Size in a Simulated Trial of Goldblatt et al. PCV13. Simulated under ...
Figure S5. Serotype-specific Prevalence Distribution After Fitting Model. Prevalence of each serotyp...
Additional file 1: Supplemental Figure S1. Vaccine roll-out scenarios. Supplemental Figure S2. Impac...
Adjusted analysis of the association of different variables with the vaccine era using linear mixed ...
Additional file 1: S1 Fig. Effects of full vaccination on the (A) case growth rate, (B) number of IC...
Figure S2. The hazard ratio (HR) for AOM-associated antimicrobial prescriptions from the cox-regress...
Abstract Background There is great interest in the use of reduced dosing schedules for pneumococcal ...
Additional file 1: Table S1. Characteristics of participants with breakthrough infections, post-vacc...
Kinetics of prevalence and evolution of OPV2-derived viruses for the exponential decay pattern in th...
Additional file 1: S1. Model Structure. S1.1. Modelling transmission. S1.2. Fitting to the basic rep...
Additional charts (Figure S1. Vaccination strategy by treatment number. Figure S2. Sensitivity of pr...
Additional file 1: Supplementary Figure 1. Directed acyclic graph (DAG) on hypothesis 2: Higher reac...
Time taken to reach the peak prevalence varies according to the household size distribution in the c...
The degree and time frame of indirect effects of vaccination (serotype replacement and herd immunity...